Tandem Diabetes Care Analyst Ratings
Oppenheimer Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $58
Strong Market Reclaim and Innovative Pipeline Underpin Buy Rating for Tandem Diabetes Care
Tandem Diabetes Care Analyst Ratings
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Tandem Diabetes Care Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Omnicell (OMCL), Tandem Diabetes Care (TNDM) and Amgen (AMGN)
Tandem Diabetes Care Analyst Ratings
Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)
Tandem Diabetes Care Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Castle Biosciences (CSTL)
Tandem Diabetes Care (TNDM) Gets a Buy From Piper Sandler
Tandem Diabetes Care Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Eli Lilly & Co (LLY)
Tandem Diabetes Care Analyst Ratings
Tandem Diabetes Care Analyst Ratings
Tandem Diabetes Care Analyst Ratings
Tandem Diabetes Care Analyst Ratings
Tandem Diabetes Care Analyst Ratings
Tandem Diabetes Care Analyst Ratings